

Special Issue

Stroke Management— Personalized Diagnostic, Therapy and Rehabilitation

Message from the Guest Editor

Stroke management has advanced considerably in recent decades, although there remain opportunities to further enhance outcomes via personalized and precision medicine approaches. Some key points in the background and history of this topic are as follows: the heterogeneity of stroke, personalized medicine, the Human Genome Project, advances in imaging, biomarkers, and omics technologies, wearables and telemedicine, AI and machine learning techniques. We look forward to contributions that showcase the immense potential to enhance the standard of care and outcomes across the many facets of stroke management via emerging precision and personalized medicine approaches. This Special Issue seeks to showcase high-quality research focused on personalized and precision medicine approaches across the spectrum of stroke management, from rapid and accurate diagnostics to targeted therapies and tailored rehabilitation plans. We welcome original research as well as review articles that synthesize the state of the art in using patient-specific biomarkers, genetics, and other factors to achieve optimal outcomes in stroke care.

Guest Editor

Dr. Wenjun Tu

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Deadline for manuscript submissions

closed (20 July 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/193943

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).